Free tool
FAERS Monitor: Arakoda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210607 or its brand name (Arakoda, Tafenoquine Succinate). Reports on generic versions are filed under their own applications.
Reports
66
Serious
57
86% of reports
Hospitalization
27
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- depression20
- anxiety18
- nausea15
- post-traumatic stress disorder15
- anger14
- tinnitus12
- headache11
- dizziness10
- memory impairment10
- mental disorder10
- off label use10
- paranoia10
- suicide attempt10
- brain injury9
- mood swings9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2018 | 23 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 11 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| post-traumatic stress disorderSignal | 15 | 714.9 | 457.9 | 9,973 |
| brain injurySignal | 9 | 286.4 | 156.0 | 2,281 |
| paranoiaSignal | 10 | 185.0 | 104.5 | 1,651 |
| angerSignal | 14 | 132.0 | 82.9 | 1,693 |
| mood swingsSignal | 9 | 90.0 | 49.0 | 707 |
| tinnitusSignal | 12 | 83.3 | 49.9 | 897 |
| mental disorderSignal | 10 | 73.3 | 41.4 | 643 |
| suicide attemptSignal | 10 | 52.6 | 29.7 | 457 |
| depressionSignal | 20 | 28.0 | 19.4 | 500 |
| memory impairmentSignal | 10 | 23.2 | 13.1 | 192 |
| anxietySignal | 18 | 20.2 | 13.6 | 313 |
| dizzinessSignal | 10 | 6.4 | 3.6 | 41 |
| nauseaSignal | 15 | 6.0 | 3.9 | 60 |
| headacheSignal | 11 | 5.6 | 3.3 | 38 |
| off label useSignal | 10 | 3.6 | 2.1 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.